NS5A

Apr 15, 2019

Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease

Jan 01, 2019

Ascletis' Ganovo Enrolled in the Basic Medical Insurance of Chengdu

Oct 18, 2018

Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA

Aug 06, 2018

Ascletis' Ravidasvir Recommended by WHO HCV Guidelines

Aug 01, 2018

Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

Jul 31, 2018

Ascletis Filed NDA for Its All-oral HCV Treatment

Jun 12, 2018

Ascletis Receives NDA Approval from China FDA for Ganovo

Sep 27, 2017

AbbVie Announces Approval of MAVIRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan

Aug 18, 2017

Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis